BACKGROUND: Prior promising results have been reported with deep brain stimulation (DBS) of the anterior limb of the internal capsule in cases with severe obsessive compulsive disorder (OCD) who had exhausted conventional therapies. METHODS: In this pilot study, six adult patients (2 male; 4 female) meeting stringent criteria for severe (minimum Yale-Brown Obsessive Compulsive Scale [Y-BOCS] of 28) and treatment-refractory OCD had DBS electrode arrays placed bilaterally in an area spanning the ventral anterior limb of the internal capsule and adjacent ventral striatum referred to as the ventral capsule/ventral striatum. Using a randomized, staggered-onset design, patients were stimulated at either 30 or 60 days following surgery under blinded conditions. RESULTS: After 12 months of stimulation, four (66.7%) of six patients met a stringent criterion as "responders" (> or =35% improvement in the Y-BOCS and end point Y-BOCS severity < or =16). Patients did not improve during sham stimulation. Depressive symptoms improved significantly in the group as a whole; global functioning improved in the four responders. Adverse events associated with chronic DBS were generally mild and modifiable with setting changes. Stimulation interruption led to rapid but reversible induction of depressive symptoms in two cases. CONCLUSIONS: This pilot study suggests that DBS of the ventral capsule/ventral striatum region is a promising therapy of last resort for carefully selected cases of severe and intractable OCD. Future research should attend to subject selection, lead location, DBS programming, and mechanisms underpinning therapeutic benefits. Copyright2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND: Prior promising results have been reported with deep brain stimulation (DBS) of the anterior limb of the internal capsule in cases with severe obsessive compulsive disorder (OCD) who had exhausted conventional therapies. METHODS: In this pilot study, six adult patients (2 male; 4 female) meeting stringent criteria for severe (minimum Yale-Brown Obsessive Compulsive Scale [Y-BOCS] of 28) and treatment-refractory OCD had DBS electrode arrays placed bilaterally in an area spanning the ventral anterior limb of the internal capsule and adjacent ventral striatum referred to as the ventral capsule/ventral striatum. Using a randomized, staggered-onset design, patients were stimulated at either 30 or 60 days following surgery under blinded conditions. RESULTS: After 12 months of stimulation, four (66.7%) of six patients met a stringent criterion as "responders" (> or =35% improvement in the Y-BOCS and end point Y-BOCS severity < or =16). Patients did not improve during sham stimulation. Depressive symptoms improved significantly in the group as a whole; global functioning improved in the four responders. Adverse events associated with chronic DBS were generally mild and modifiable with setting changes. Stimulation interruption led to rapid but reversible induction of depressive symptoms in two cases. CONCLUSIONS: This pilot study suggests that DBS of the ventral capsule/ventral striatum region is a promising therapy of last resort for carefully selected cases of severe and intractable OCD. Future research should attend to subject selection, lead location, DBS programming, and mechanisms underpinning therapeutic benefits. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Authors: Arif Khan; Russell L Kolts; Mark H Rapaport; K Ranga Rama Krishnan; Amy E Brodhead; Walter A Browns Journal: Psychol Med Date: 2005-05 Impact factor: 7.723
Authors: Benjamin D Greenberg; Lawrence H Price; Scott L Rauch; Gerhard Friehs; Georg Noren; Donald Malone; Linda L Carpenter; Ali R Rezai; Steven A Rasmussen Journal: Neurosurg Clin N Am Date: 2003-04 Impact factor: 2.509
Authors: N A Shapira; M S Okun; D Wint; K D Foote; J A Byars; D Bowers; U S Springer; P J Lang; B D Greenberg; S N Haber; W K Goodman Journal: J Neurol Neurosurg Psychiatry Date: 2006-03 Impact factor: 10.154
Authors: B D Greenberg; L A Gabriels; D A Malone; A R Rezai; G M Friehs; M S Okun; N A Shapira; K D Foote; P R Cosyns; C S Kubu; P F Malloy; S P Salloway; J E Giftakis; M T Rise; A G Machado; K B Baker; P H Stypulkowski; W K Goodman; S A Rasmussen; B J Nuttin Journal: Mol Psychiatry Date: 2008-05-20 Impact factor: 15.992
Authors: Donald A Malone; Darin D Dougherty; Ali R Rezai; Linda L Carpenter; Gerhard M Friehs; Emad N Eskandar; Scott L Rauch; Steven A Rasmussen; Andre G Machado; Cynthia S Kubu; Audrey R Tyrka; Lawrence H Price; Paul H Stypulkowski; Jonathon E Giftakis; Mark T Rise; Paul F Malloy; Stephen P Salloway; Benjamin D Greenberg Journal: Biol Psychiatry Date: 2008-10-08 Impact factor: 13.382
Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1989-11
Authors: Thomas E Schlaepfer; Michael X Cohen; Caroline Frick; Markus Kosel; Daniela Brodesser; Nikolai Axmacher; Alexius Young Joe; Martina Kreft; Doris Lenartz; Volker Sturm Journal: Neuropsychopharmacology Date: 2007-04-11 Impact factor: 7.853
Authors: Claudio Da Cunha; Suelen L Boschen; Alexander Gómez-A; Erika K Ross; William S J Gibson; Hoon-Ki Min; Kendall H Lee; Charles D Blaha Journal: Neurosci Biobehav Rev Date: 2015-02-12 Impact factor: 8.989
Authors: Matthew F DiFrancesco; Casey H Halpern; Howard H Hurtig; Gordon H Baltuch; Gregory G Heuer Journal: Childs Nerv Syst Date: 2012-07-25 Impact factor: 1.475
Authors: Gonçalo Cotovio; Daniel Talmasov; J Bernardo Barahona-Corrêa; Joey Hsu; Suhan Senova; Ricardo Ribeiro; Louis Soussand; Ana Velosa; Vera Cruz E Silva; Natalia Rost; Ona Wu; Alexander L Cohen; Albino J Oliveira-Maia; Michael D Fox Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808